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Abstract
Introduction: Although Pseudomonas aeruginosa is a leading pathogen responsible for ventilator-associated
pneumonia (VAP), the excess in mortality associated with multi-resistance in patients with P. aeruginosa VAP
(PA-VAP), taking into account confounders such as treatment adequacy and prior length of stay in the ICU, has
not yet been adequately estimated.
Methods: A total of 223 episodes of PA-VAP recorded into the Outcomerea database were evaluated. Patients with
ureido/carboxy-resistant P. aeruginosa (PRPA) were compared with those with ureido/carboxy-sensitive P.
aeruginosa (PSPA) after matching on duration of ICU stay at VAP onset and adjustment for confounders.
Results: Factors associated with onset of PRPA-VAP were as follows: admission to the ICU with septic shock, broad-
spectrum antimicrobials at admission, prior use of ureido/carboxypenicillin, and colonization with PRPA before
infection. Adequate antimicrobial therapy was more often delayed in the PRPA group. The crude ICU mortality rate
and the hospital mortality rate were not different between the PRPA and the PSPA groups. In multivariate analysis,
after controlling for time in the ICU before VAP diagnosis, neither ICU death (odds ratio (OR) = 0.73; 95%
confidence interval (CI): 0.32 to 1.69; P = 0.46) nor hospital death (OR = 0.87; 95% CI: 0.38 to 1.99; P = 0.74) were
increased in the presence of PRPA infection. This result remained unchanged in the subgroup of 87 patients who
received adequate antimicrobial treatment on the day of VAP diagnosis.
Conclusions: After adjustment, and despite the more frequent delay in the initiation of an adequate antimicrobial
therapy in these patients, resistance to ureido/carboxypenicillin was not associated with ICU or hospital death in
patients with PA-VAP.
Introduction
Despite many improvements in the management of
mechanically-ventilated patients, ventilator-associated
pneumonia (VAP) remains the second leading cause of
nosocomial infections in intensive care units (ICU).
VAP has one of the highest mortality rates, ranking
from 20 to 50% [1], and increases length of hospital
stay, and hospital costs [2].
Pseudomonas aeruginosa is a leading cause of nosoco-
mial infections and one of the bacteria most frequently
responsible for late-onset VAP. When VAP is documen-
ted by bronchoscopic techniques, P. aeruginosa is the
most frequently isolated nosocomial bacteria, with more
than 19% of the isolates. According to data collected by
the French network REA-RAISIN during the year 2009,
P. aeruginosa was the bacteria responsible for most
nosocomial infections (17.3% of nosocomial infections)
and for most VAP (22.3% of VAP) [3].
P. aeruginosa causes infection and damage to host tis-
sues via the production of several extracellular virulence
factors [4-7]. The P. aeruginosa genome is one of the
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genetic and functional diversity, with a large number of
genes predicted to encode outer membrane proteins
such as those involved in adhesion, motility, antibiotic
efflux and virulence factor export [8].
In addition to being intrinsically resistant to several anti-
microbial agents, P. aeruginosa often acquires mechanisms
of resistance to other antibiotics, especially in ICU
patients. This increasing antibiotic resistance makes the
treatment of P. aeruginosa ventilator-associated pneumo-
nia (PA-VAP) more difficult and more expensive.
Few published studies report the impact of antibiotic
resistance on the outcome of PA-VAP [9,10]. Their
authors conclude that antibiotic resistance did not sig-
nificantly affect ICU mortality. However, appropriate
adjustments for differences in epidemiological and clini-
cal characteristics between patients with resistant and
susceptible infections are complex, leading to results
lacking in controls for confounding factors.
The goal of this study was to estimate the mortality
attributable to piperacillin resistance, while taking into
account differences in the elapsed time between disease
onset and the initiation of an adequate antimicrobial
therapy.
Material and methods
Study design and data source
We conducted an exposed/non-exposed study nested in
a multicenter cohort (the OUTCOMEREA
® database)
from January 1997 to January 2008. The database, fed
by 12 French ICUs, is designed to record daily disease
severity and occurrence of iatrogenic events.
The senior physicians of the participating ICUs, who
are closely involved in establishing the database,
recorded the data daily. For each patient, the investiga-
tors entered the data into a computer case-report form
using the data capture softwares VIGIREA and recently
RHEA
® (OUTCOMEREA™, Rosny-sous-Bois, France).
All records were imported to the OUTCOMEREA
®
database. All codes and definitions were defined in writ-
ing before the start of the data collection.
The following data were collected: age, sex, comorbid-
ities assessed according to the Acute Physiology and
Chronic Health Evaluation (APACHE) II definitions
[11], severity of illness both at ICU admission and daily
during the ICU stay assessed using the Simplified Acute
Physiology Score (SAPS) II [12] and the Logistic Organ
Dysfunction (LOD) score [13], admission category (med-
ical, scheduled surgery, or unscheduled surgery), admis-
sion diagnosis, whether the patient was transferred from
a hospital ward (defined as a stay in an acute-bed ward
≥24 hours immediately before ICU admission), lengths
of ICU and hospital stays, and vital status at discharge
from ICU and from the hospital. Invasive procedures
(placement of an arterial or central venous catheter, and
endotracheal intubation), treatments of organ failure
(catecholamine infusion, mechanical ventilation, hemo-
dialysis), and antibiotic use were also captured.
Suspected VAP was defined as the development of per-
sistent pulmonary infiltrates on chest radiographs com-
bined with purulent tracheal secretions and/or body
temperature ≥38.5°C or ≤36.5°C and/or peripheral blood
leukocyte count ≥10·10
9/L or ≤4·10
9/L. Before receiving
any new antibiotic therapy, all patients with suspected
VAP underwent fiber optic bronchoscopy with a protected
specimen brush and/or bronchoalveolar lavage (BAL),
single-sheathed blind plugged telescopic catheter speci-
men collection, or tracheal aspiration, with quantitative
cultures of collected specimens. The model was estab-
lished using solely confirmed VAP. This was defined as a
positive culture result from a protected specimen brush
(≥10
3 cfu/ml), plugged telescopic catheter specimen (≥10
3
cfu/ml), BAL fluid specimen (≥10
4 cfu/ml), or quantitative
endotracheal aspirate (≥10
5 cfu/ml) [14]. The investigators
recorded prospectively the date of appropriate therapy
start (that is, the date when at least one of the antibiotics
had in vitro activity against the strains recovered) but the
complete antimicrobial susceptibility testing results were
not captured in the OUTCOMEREA
® database.
A special request was performed retrospectively to
collect information about antibiotic susceptibility pro-
files of all recovered strains of P. aeruginosa.S t r a i n s
intermediate or resistant to one antimicrobial were con-
sidered as resistant.
The quality control processes are detailed elsewhere
[14]. Briefly, it combined an initial training process, a
manual, and automatic checking for inconsistencies and
feedback to investigators, a data-capture training course,
and a bi-annual audit of patients’ files. Moreover, each
ICU investigator was involved in the data analysis and
study reporting.
Study population and definitions
All patients in the database with a confirmed PA-VAP
were eligible.
Patients with mechanical ventilation at admission who
developed a resistant PA-VAP were compared to
patients who developed sensitive PA-VAP. Among
patients who contracted several episodes of PA-VAP,
only the first episode was included in the analysis. We
compared patients with a first episode of PA-VAP due
to Ureido/carboxypenicillin sensitive (PSPA-VAP) to
those having resistant strains (PRPA-VAP).
Statistical analyses
Results are expressed as numerical values and percen-
tages for categorical variables, and as medians and inter-
quartiles (Q1 to Q3) for continuous variables.
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on the duration of the ICU stay prior to PA-VAP onset.
Comparisons between matched patients were initially
completed based on univariate conditional logistic
regression. Multivariate conditional logistic regression
was then used to examine the association between
PRPA-VAP and ICU and hospital mortality. This was
adjusted for potential confounding variables (that is,
variables that had a P-value ≤10 in bivariate analysis).
Wald c
2 tests were used to determine the significance of
each variable. Adjusted odds ratios (OR) and 95% confi-
dence were calculated for each parameter estimate. A
P-v a l u el e s st h a n. 0 5w a sc o n s i d e r e ds i g n i f i c a n t .A n a -
lyses were computed using the SAS 9.1 software package
(SAS Institute, Cary, NC, USA)
Ethical issues
According to French law, this study did not require
p a t i e n tc o n s e n t ,a si ti n v o l v e dr e s e a r c ho nad a t a b a s e .
The study was approved by the institutional review board
of the Centres d’Investigation Rhône-Alpes-Auvergne.
Results
During the study period, of the 9,985 patients included
in our OUTCOMEREA
® database, 4,422 received
mechanical ventilation for more than two days, and 223
experienced at least one episode of PA VAP (361 epi-
sodes of PA VAP were recorded). PRPA-VAP was diag-
nosed in 70 patients, and PSPA-VAP was diagnosed in
153 patients (Table 1). Resistance to other antimicro-
b i a l sw e r ea sf o l l o w s :i m i p e n e m( 2 5 . 6 % ,2 6n o t
recorded), ceftazidime (83.8%, 19 not recorded), cipro-
floxacin (38.5%, 55 not recorded), amikacin (17.2%, 25
not recorded), colistin (4.2%, 80 not recorded). The
median length of ICU stay was 29 days. The flowchart
of the study is shown in Figure 1.
Factors associated with Ureido-/carboxypenicillin
resistance
Clinical characteristics at ICU admission and within
48 hours before VAP diagnosis for PRPA and PSPA-
VAP are listed in Table 2. The groups were similar with
regard to sex, age, SAPS II, immunosuppression, under-
lying diseases and proportions of medical and surgical
patients.
Patients with PRPA-VAP were more likely to have
septic shock at ICU admission (28.6% (20 of 70 patients)
vs. 15% (23 of 153 patients); P = 0.02), and to have a
previous carriage or colonization with a multiresistant
strain of PA. Positive blood culture (between Day -2
VAP diagnosis and Day +2) was more frequent in the
PRPA-VAP than in the PSPA-VAP group (10% (7 of 70
patients) vs. 3.9% (6 of 153 patients); P = 0.054).
Details of antimicrobials received prior to VAP infec-
tion are listed in Table 3. Compared to patients with
PSPA-VAP, patients with PRPA-VAP were significantly
more likely to have received broad-spectrum antimicro-
bials during their admission in the ICU (77.1% (54 of 70
patients) vs. 60.1% (92 of 153 patients); P = 0.03). Before
VAP diagnosis, patients with PRPA-VAP were more
likely to have received tazobactam therapy (18.6% (13 of
70 patients) vs. 9.2% (14 of 153 patients); P =0 . 0 1 ) ,a n d
to have received ureidopenicillins or carboxypenicillins
therapy (31.4% (22 of 70 patients) vs. 13.1% (20 of 153
patients); P = 0.0004). Differences in the use of fluoro-
quinolones therapy did not reach statistical significance
( 2 4 . 3 %i nP R P Ag r o u p( 7o f7 0p a t i e n t s )v s .1 3 . 1 %i n
PSPA group (20 of 153 patients); P = 0.058).
Percentage of antibiotic-free days was different
between the two groups for tazobactam, and ureidopeni-
cillins-carboxypenicillins. Compared with patients with
PRPA-VAP, patients with PSPA-VAP had more tazobac-
tam-free days (P = 0.019), and less ureidopenicillins-
carboxypenicillins-free days (P = 0.007).
Adequate antibiotic therapy was started within 24 h
after the diagnosis of VAP for 36 patients (51.4%) in the
PRPA-VAP group, versus 117 patients (76.5%) in the
PSPA-VAP group (P = 0.001). Adequate antibiotic ther-
apy was started at least two days after PA VAP diagnosis
for 25 patients (35.7%) in the PRPA-VAP group, versus
for 26 patients (17%) in the PSPA-VAP group (P =
0.007). Use of bi- or tri-antimicrobial-therapy was simi-
lar between groups. Antibiotic therapy before ICU
discharge was not adequate for 9 patients (12.9%) in the
PRPA-VAP group, versus 10 patients (6.5%) in the
PSPA-VAP group (P = 0.054).
The rate of recurrence was not influenced by resis-
tance (PSPA-VAP 28 (18.3%) vs PRPA-VAP 11 (15.7%),
P = 0.83).
Compared with patients with PSPA-VAP, PRPA-VAP
patients had similar lengths of ICU stay prior to VAP
(11 days (range, 6 to 18 days) vs. 9 days (range, 6 to 17
days); P = 0.53). PRPA-VAP and PSPA-VAP were asso-
ciated with similar crude ICU mortality (38% (25 of 70
patients) vs. 41% (62 of 153 patients); P =0 . 5 6 )a sw e l l
as in hospital mortality (43% (30 of 70 patients) vs. 44%
(68 of 153 patients); P = 0.85).
Risk factors for death
Risk factors for ICU death are listed in Table 1. Risk
factors found for ICU death at admission were: age, at
least one chronic illness, admission for cardiac illness or
septic shock, Simplified Acute Physiology Score version
II (SAPS II), organ dysfunction scores (LOD, SOFA).
Two days before PA-VAP, risk factors for ICU death
were: treatment with vasopressors, treatment with
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SOFA).
Resistance to Ureido/carboxypenicillin was not a risk
factor for ICU death. After adjusting for other risk fac-
tors of death, differences between groups and duration
of ICU stay prior to the VAP onset, resistance to
ureido/carboxypenicillins was no more a risk factor for
death (Table 4).
Similarly, resistance to imipenem, ceftazidime, amika-
cin, ciprofloxacin and colistin (Figure 2) was not asso-
ciated with ICU death or hospital death.
The results remained unchanged when analysis was
restricted to the 87 patients adequately treated the day
of the infection onset (OR for ICU mortality 1.22 (95%
C I ,0 . 3 1t o4 . 7 8 ;P = 0.78); OR for hospital mortality,
1.10 (95% CI, 0.29 to 4.10; P = 0.89)).
Discussion
To date, our study is one of the largest to have evalu-
ated the impact of piperacillin resistance in PA-VAP
[9,10]. All data were carefully recorded by senior physi-
cians on computer forms. Definitions and antimicrobial
Table 1 Risk factors of ICU death
Variables Survivors (n = 136) Deaths (n = 87) P
Male sex 105 (77) 69 (79) 0.86
Age 66 (52 to 76) 70 (57 to 77) 0.04
Category at admission Medical 90 (66) 62 (71) 0.49
Emergency surgery 25 (18) 17 (19) 0.76
Scheduled surgery 21 (15) 8 (9) 0.20
Severity score at admission LOD 6 (4 to 8) 7 (5 to 10) 0.04
SAPS II 45 (36 to 53) 54 (42 to 66) 0.0001
SOFA 8 (6 to 10) 9 (6 to 11) 0.03
Duration of ICU stay before VAP 10 (6 to 18) 9 (5 to 18) 0.13
Duration of stay ICU 32 (20 to 50) 26(14 to 41) 0.19
Hospital 57 (42 to 84) 30 (19 to 59) <0.0001
Main diagnosis at admission Septic shock 25 (18) 18 (21) 0.74
Multiple organ failure 6 (4) 6 (7) 0.26
Cardiac failure 5 (4) 2 (2) 0.53
Acute respiratory failure 47 (35) 27 (31) 0.59
COPD exacerbation 9 (7) 5 (6) 0.96
Acute renal failure 3 (2) 2 (2) 0.90
Scheduled surgery 9 (7) 1 (1) 0.08
Chronic illness Cardiovascular 16 (12) 19 (22) 0.03
Pulmonary 31 (23) 22 (25) 0.58
Renal 6 (4) 4 (5) 0.90
Hepatic 6 (4) 7 (8) 0.29
Diabetes 20 (15) 9 (10) 0.73
At least one chronic illness 59 (43) 51 (59) 0.02
Treatment at admission Vasopressors 84 (62) 59 (68) 0.30
Steroids 39 (29) 35 (40) 0.05
Broad-spectrum antimicrobials 88 (65) 58 (67) 0.45
Hemodialysis/hemofiltration 14 (10) 8 (9) 0.91
Polymicrobial VAP 34 (25) 29 (33) 0.27
SOFA score at VAP onset 5 (3 to 7) 7 (4 to 9) 0,0004
Adequate antimicrobial treatment* J 0 53 (39) 34 (39) 0.42
J+1 41 (30) 25 (29) 0.66
J+2 32 (23) 19 (22) 0.40
Antimicrobials Monotherapy 15 (12) 17 (22) 0.12
Bi or Tri antibiotic therapy 111 (82) 61 (70) 0.11
Data are the number (%) of patients (minimum to maximum). ICU, intensive care unit; LOD, logistic organ dysfunction; PRPA, piperacillin resistant Pseudomonas
aeruginosa; PSPA, piperacillin sensitive Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score version II; SOFA, Simplified Organ Failure Assessment;
VAP, ventilator-associated pneumonia.
(*) nb of calendar day between the suspicion of VAP/bacteriological sampling and the initiation of an antimicrobial treatment effective on recovered micro-
organisms.
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lines. The major result is that piperacillin resistance is
associated with a higher rate of inappropriate antimicro-
bial therapy. Unadjusted mortality was similar in PSPA-
VAP and PRPA-VAP groups. After careful adjustment
for time in the ICU at VAP diagnosis and for para-
meters that differ between the PRPA and the PSPA
groups (severity at admission, previous antibiotic treat-
ment, and adequacy of antimicrobial treatment), pipera-
cillin resistance was found to not be associated with
ICU or hospital death in the multivariate logistic regres-
sion analysis.
We observed a high rate of P. aeruginosa strains resis-
tant to piperacillin (31%). This is in agreement with pre-
vious studies conducted in Europe [16]. The percentage
of P. aeruginosa resistance to ureidopenicillin reached
37% in the EPIC I study which included only bacterial
strains from the European ICU [17]. The pathogenicity
of P. aeruginosa is multifactorial, strain-specific, and
dependent on complex host factors. Morbidity and mor-
tality for patients infected with piperacillin resistant
P. aeruginosa might be related to the virulence of the
bacteria but also to the antimicrobial treatment adminis-
tered. Both virulence factor genes and antimicrobial
resistance genes are mostly carried by transposons and
integrons, that is, genetic entities able to mediate their
own translocation from one DNA site to another one.
Integrons are particularly dominant contributors to the
development of multi-drug resistant P. aeruginosa
strains [8].
Figure 1 Flowchart of the study. PA-VAP, Ventilated Associated Pneumonia due to Pseudomonas aeruginosa; PRPA, piperacillin resistant
Pseudomonas aeruginosa; PSPA, piperacillin sensitive Pseudomonas aeruginosa
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intensive care unit
Characteristics PSPA-VAP N = 153 PRPA-VAP N = 70 P
a
Male sex 119 (78) 55 (79) 0.75
Age 68 (55 to 76) 66 (49 to 77) 0.54
Type of admission Medical 106 (69) 46 (66) 0.83
Surgical 27 (18) 15 (21) 0.53
Scheduled 20 (13) 9 (13) 0.65
SAPS II 48 (38 to 61) 48 (38 to 55) 0.80
Main diagnosis at admission Septic shock 23 (15) 20 (29) 0.02
Multiple organ failure 8 (5) 4 (6) 0.79
Cardiovascular failure 6 (4) 1 (1) 0.64
Respiratory failure 55 (36) 19 (27) 0.14
Acute respiratory exacerbation of
chronic pulmonary diseases
9 (6) 5 (7) 0.61
Acute renal failure 4 (3) 1 (1) 0.57
Scheduled surgery 4 (3) 6 (9) 0.02
Treatments within 48 hrs of ICU admission Vasopressors 101 (66) 42 (60) 0.25
Steroids 50 (33) 24 (34) 0.67
Broad-spectrum antimicrobials 92 (60) 54 (77) 0.03
Duration of ICU stay before VAP 9 (6 to 17) 11 (6 to 18) 0.23
Organ dysfunction scores the day before VAP LOD 5 (3 to 7) 4.5 (3 to 7) 0.56
SOFA 6 (3 to 8) 5 (3 to 7) 0.77
Polymicrobial VAP 45 (29) 18 (26) 0.53
Positive blood culture 6 (4) 7 (10) 0.11
Duration of stay ICU 29 (17 to 48) 28,5 (18 to 48) 0.37
Hospital 47.5 (28 to 72) 50 (28 to 68) 0.24
Data are the number (%) of patients (minimum to maximum). ICU, intensive care unit; LOD, logistic organ dysfunction; PRPA, piperacillin resistant Pseudomonas
aeruginosa; PSPA, piperacillin sensitive Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score version II; SOFA, Simplified Organ Failure Assessment;
VAP, ventilator-associated pneumonia.
aWald c
2 test in conditional regression.
Table 3 Antimicrobials received in the ICU within the
seven days prior to VAP onset
Antimicrobials PSPA-
VAP
(n = 153)
PRPA-
VAP
(n = 70)
P-value
Penicillin 63 (41) 21 (30) 0.27
Cephalosporins 1, 2 or 3 46 (30) 22 (31) 0.99
Ceftazidime 7 (5) 3 (4) 0.99
Cephalosporins 4 (cefepim, cefpirome) 4 (3) 5 (7) 0.19
Piperacillin-Tazobactam 14 (9) 13 (19) 0.01
Ureidopenicillin - carboxypenicillin 20 (13) 22 (31) 0.0004
Tazobactam, sulbactam or Clavulanic
acid
56 (37) 26 (37.1) 0.41
Penems 11 (7) 6 (8.6) 0.92
Fluoroquinolones 20 (13) 17 (24.3) 0.058
Aminoglycosides 38 (25) 21 (30) 0.24
Azoles 16 (10) 13 (19) 0.14
Glycopeptides 24 (16) 14 (20) 0.42
Other 14 (9) 8 (11) 0.99
At least one antimicrobial 101 (66) 44 (63) 0.60
Data are the numbers (%).
Table 4 Multivariate analysis, factors associated with ICU
and hospital death after adjusting on potential
confounding factors
OR 95% CI P-value
ICU death
At least one chronic illness 2.47 1.24 to 4.92 0.01
Fluoroquinolones prior VAP onset 2.45 0.91 to 6.63 0.08
Positive blood culture 5.11 1.16 to 22.6 0.03
LOD two days before infection (per point) 1.17 1.01 to 1.37 0.04
SAPS at admission (per point) 1.03 1.00 to 1.05 0.04
PRPA-VAP 0.73 0.32 to 1.69 0.46
Hospital Death
At least one chronic illness 2.29 1.16 to 4.54 0.02
Fluoroquinolones prior VAP onset 2.89 1.04 to 8.04 0.04
Positive blood culture 4.58 0.96 to 21.9 0.05
SAPS II at admission 1.04 1.01 to 1.06 0.01
PRPA-VAP 0.87 0.38 to 1.99 0.74
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PSPA strains. P. aeruginosa exhibits multiple virulence
factors: some surface factors including flagellum, pili,
LPS, some secreted factors including a type III secretion
system that confers the ability to inject toxins into host
cells; quorum-sensing molecules (a complex regulatory
circuit involving cell-to-cell signalling) and alginate.
Some studies conducted in vitro and in experimental
models found that virulence of P. aeruginosa might be
reduced in mutant resistant strains of P. aeruginosa sug-
gesting that antibiotic resistance imposes a fitness cost
on the bacteria [18,19]. Recent data on in vitro mutants
have suggested that virulence of P. aeruginosa might be
reduced when mex efflux systems are overexpressed
[20]. Indeed, it seems that mutant strains may recover
their fitness or virulence by compensatory mutations.
Hoquet et al. conducted a study on 120 strains of
P. aeruginosa from episodes of septicaemia: 75% of
strains displayed a significant resistance to one or more
of the tested antimicrobials. P. aeruginosa may accumu-
late intrinsic (chromosomal) and exogenous resistance
mechanisms without losing its ability to generate severe
bloodstream infections [21].
Jeannot et al. focused on clinical isolates of P. aerugi-
nosa mexCD-oprJ overproducing efflux mutants:
mexCD-oprJ up regulation (which correlated with
increase resistance to ciprofloxacin and cefepime,
increased susceptibility to ticarcillin, aztreonam, imipe-
nem and aminoglycosides), associated with impaired
bacterial fitness although it was isolated from confirmed
cases of clinical infections [22].
In our study, 153 of 223 patients received adequate
antibiotic therapy within 24 hours after pneumonia
suspicion (51.4% in the PRPA group and 76.5% in the
PSPA group). Garnacho-Montero et al. [23] evaluated
the impact on the outcome of a monotherapy or a com-
bined therapy in patients with PA-VAP. They showed
that the initial use of a combination therapy significantly
reduced the likelihood of inappropriate therapy, which
was associated with a higher risk of death. However, the
administration of only one effective antimicrobial or
combination therapy provided similar outcomes. For
Kang et al. adequate initial antibiotic therapy appeared
to be one of the most important factors in the treatment
of severe P. aeruginosa infections, as they observed a
trend towards higher mortality rates as the interval prior
to appropriate treatment increased. However, their
results were not statistically significant [24].
In our study, antibiotic resistant strains were asso-
ciated with an increased risk of inadequate antimicrobial
therapy, but we did not find that PRPA influenced
recurrence, relapse or mortality.
We previously showed that the highest impact of inap-
propriate therapy on prognosis obtained when patients’
severity score is intermediate [25,26]. The absence of
impact of inappropriate antimicrobial therapy on the
prognosis might be due to the high severity of patients
at VAP onset (SOFA at 6 in median in the present
study).
As any delay in the initiation of an adequate antimi-
crobial therapy is known to be a major prognostic risk
factor in nosocomial infection due to P. aeruginosa
[24,27], the absence of an increased mortality, where the
initial antibiotic therapy is less often appropriate, would
plead in favour of impaired virulence of the resistant
strains.
Figure 2 Resistance to other antimicrobials of ureido/carboxy susceptible and resistant strains (n = 129). AMK, amikacine; CFP, cefepime;
CIP, ciprofloxacin; COL, colimycin; CTZ, Ceftazidime; IMI, Imipenem; PR-PA piperacillin-resistant P. aeruginosa; PSPA, piperacillin-susceptible P.
aeruginosa; (*) Missing values: some antibiotics were not tested by the microbiology lab or not found, CTZ 2 (1%), CFP 63 (31%), IMI 7 (3%), CIP
10 (5%), AMK 8 (4%), COL 60 (30%). All the differences were statistically significant (P < 0.05).
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we analysed the subgroup of 87 patients adequately trea-
ted within 24 hours after VAP diagnosis. In the multi-
variate analysis, the only risk factor of ICU or hospital
death was having at least one chronic illness, not pipera-
cillin resistance.
Other studies comparing outcomes of susceptible and
resistant P. aeruginosa infections are scarce. Recently,
Combes et al. conducted a post-hoc analysis of the
PNEUMA randomized study, which involved only cases
of adequately treated PA VAP [9]. PRPA-VAP was asso-
ciated with a higher mortality than PSPA-VAP. How-
ever, after adjustment for age, female gender, underlying
comorbidities, and SOFA score, piperacillin resistance
was no longer associated with mortality (OR, 2.00; 95%
CI, 0.72 to 5.61; P = 0.194). Similarly, in a retrospective
cohort study evaluating the epidemiological characteris-
tics of 135 episodes of VAP caused by PRPA or PSPA,
Trouillet et al. did not find any increased death rates for
PRPA infections [10]. Data from the few studies con-
cerning P.aeruginosa bacteraemia reported similar
results. Blot et al. conducted a retrospective study on
antibiotic-susceptible and antibiotic-resistant nosocomial
gram-negative bacilli bacteraemia in critically ill patients.
Factors associated with in-hospital mortality were the
age, a high-risk source of bacteraemia, and APACHE II
score, but not antibiotic resistance [28]. This result is in
accordance with other studies conducted about gram-
negative bacilli infection [29], as well as Staphylococcus
aureus pneumonia [30].
Some studies have described higher mortality rates in
association with infections caused by antibiotic resistant
P. aeruginosa. In a retrospective matched control study
by Aloush et al., patients infected with multi-resistant P.
aeruginosa strains had higher mortality rates and
increased durations of hospital stay, but the control
patients did not have P. aeruginosa infections [31]. In an
older study evaluating health and economic outcomes of
resistant Pseudomonas infections, the same group found
that, although the patients with resistant strain at hospi-
tal admission did not have a poorer overall prognosis,
the emergence of resistant strains during the hospital
stay was associated with a prolonged length of stay and
a higher hospital mortality rate [32].
Our study highlighted the major role of previous anti-
biotic therapy. The emergence of PRPA: PRPA VAP epi-
sodes were significantly associated with the
administration of broad-spectrum antimicrobials at
admission to ICU, such as ureidopenicillins, carboxype-
nicillins or fluoroquinolones. These findings are in
accordance with the results of Harris et al. [33], who
found that the piperacillin-tazobactam exposure was the
major factor that predispose for the development of an
infection with a multidrug resistant P. aeruginosa.I na
clinical study, Reinhardt et al. f o u n dt h a tr e s i s t a n t
P. aeruginosa is selected in less than seven days in
patients treated with piperacillin-tazobactam [34].
In contrast to previous studies [32,33,35], in our work,
imipenem was not associated with VAP due to PRPA.
B u tt h em a i nr e s i s t a n c em e c h a n i s mt oc a r b a p e n e mi s
loss of the porin oprD, which leads to a selective resis-
tance to these antibiotics.
Our study confirms results of the case-control study
conducted by Harris et al. in that previous exposure to
piperacillin: piperacillin-tazobactam was statistically
associated with the isolation of piperacillin-tazobactam-
resistant P. aeruginosa (OR 8.63; 95% CI 6.11 to 12.20;
P < 0.0001) [33]. In an observational study comparing
the relative risks of emergence of resistant P. aeruginosa
associated with four individual antipseudomonal agents,
Carmeli et al. demonstrated that there was an significant
association between piperacillin treatment and the emer-
gence of piperacillin resistance (HR = 5.2; P = 0.01) [32].
In our study, fluoroquinolones treatment in the week
prior to VAP was an independent factor associated with
hospital death. Few data could explain this result. The
expression of mexAB-oprM, responsible for acquired
resistance to fluoroquinolones is regulated by the
quorum-sensing, and, therefore, is known to be growth-
phase dependent [36,37]. We suggest that the
overexpression of the porin mexAB-oprM could be syn-
chronized with a hyper-production of bacterial virulence
factors, leading to a very virulent bacterial inoculum.
Results on the role of fluoroquinolones in the emer-
gence of piperacillin-resistant P. aeruginosa were of bor-
derline statistical significance. Trouillet et al. suggested
that receiving any fluoroquinolone may be a risk factor
for acquiring piperacillin-resistant P. aeruginosa [10]. In
a cohort study, Carmeli et al. also found previous cipro-
floxacin treatment was a risk factor of the emergence of
antibiotic-resistant P. aeruginosa (hazard ratio 9.2; P =
0.04) [32]. But in contrast to these previous studies, we
did not found any role of carpapenems in the emer-
gence of PRPA.
Duration of exposure to these antibiotics should also
be taken into consideration. In a case-control study con-
ducted by Paramythiotou et al., among 34 patients with
multi-drug resistant P. aeruginosa, a previous treatment
with ciprofloxacin or imipenem was a significant risk
factor for the acquisition of multi-drug resistance only
when the duration of the treatment was longer than the
median duration of treatment with these antimicrobials
observed in that study [38].
Our study has several limitations. First, we used data
prospectively collected in a large database that was not
specifically designed for the present subject. However,
all data were collected prospectively, with special atten-
tion to nosocomial infections and treatment adequacy.
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Page 8 of 10VAP was consistently documented by quantitative cul-
tures of distal pulmonary specimens, and all patients
were observed until ICU and hospital discharge.
Second, we have no data about MICs of strains to
antimicrobials and we did not determine plasma antimi-
crobial levels. PK/PD optimization may have affected
the outcome of VAP. However, antimicrobials used in
the study’s ICUs comply with international guidelines
and aminoglycosides were used when appropriate.
Conclusions
In summary, after controlling for the duration of
mechanical ventilation before VAP, piperacillin resis-
tance is not significantly associated with ICU death or
hospital death in patients with PA-VAP, despite the
more frequent delay in the initiation of an adequate
antimicrobial therapy observed in the PRPA group. This
result pleads in favour of an impaired virulence of the
resistant strains of P. aeruginosa, and should be con-
firmed by further studies conducted by physicians and
bacteriologists.
Key messages
￿ P. aeruginosa resistance to ureido/carboxypenicillin
is associated with a significant decrease of adequacy
of probabilistic antimicrobial therapy.
￿ The absence of over-mortality associated with
resistance may suggest a lower virulence of the more
resistant pseudomonas aeruginosa strains.
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